07/16/10   |   By

FDA Discredits Avandia Safety Study | DC Metro Area Medical Malpractice Law Blog

5 stars

Dr. Thomas Marciniak, a reviewer for the U.S. Food and Drug Administration, has sharply critiqued GlaxoSmithKline’s clinical trial of Avandia, GlaxoSmithKline’s popular diabetes drug.  The study flatly ignored 12 instances of heart problems among the participants.  Studies have demonstrated that Avandia also increases the risk of fractures, swelling, heart attacks, strokes, and death. One patient in the study suffered a brain bleed, but the records of this complication were reportedly deleted.  Another patient spent nine weeks in the hospital for a stroke, but that patient’s records apparently did not reflect the catastrophic event.

GlaxoSmithKline’s spokesperson was reported as responding by defending the study, “The Record study was conducted according to good clinical practices and the data are reliable.”

The FDA’s safety panel is meeting this week to decide whether Avandia, which had sales of $3.2 billion in 2006, should be pulled from the market or whether the warnings need to be strengthened regarding the complications associated with this medication.

Regan Zambri Long
Posted In
Medication Safety
Share This Article

Frequently Asked Questions

Schedule a Free Consultation

Have you or your loved one sustained injuries in Washington DC, Maryland or Virginia? Regan Zambri Long PLLC has the best lawyers in the country to analyze your case and answer the questions you may have.

Call 202-960-4596

  • Please do not send any confidential or sensitive information in this form. This form sends information by non-encrypted email, which is not secure. Submitting this form does not create an attorney-client relationship.

  • This field is for validation purposes and should be left unchanged.
Back to Top